Arcus Biosciences Inc. – Material Contracts Watch

from 10-Q 8 pages Dear Ms. Jarrett: This Letter Sets Forth the Substance of Your Separation and Release Agreement (The “Agreement”) With Arcus Biosciences, Inc. (The “Company”) in Connection With Your Resignation From the Company. 1.separation. Your Last Day of Work With the Company and Your Employment Termination Date Will Be March 30, 2026 (The “Separation Date”). You Resign Your Position of Chief Operating Officer of the Company Effective on the Separation Date. 2.accrued Salary and Paid Time Off. on the Separation Date, the Company Will Pay You All Accrued Salary and All Accrued and Unused Vacation Earned Through the Separation Date, Subject to Standard Payroll Deductions and Withholdings. You Are Entitled to This Payment by Law. 3. Advisory Services

from 10-K 2 pages [***] = Information Has Been Omitted Because It Is Both Not Material and Is the Type of Information That Arcus Biosciences, Inc. Treats as Private or Confidential Amendment No. 5 to Option, License and Collaboration Agreement

from 10-K 13 pages [***] = Information Has Been Omitted Because It Is Both Not Material and Is the Type of Information That Arcus Biosciences, Inc. Treats as Private or Confidential Amendment No. 2 to the Option and License Agreement

from 8-K 2 pages Arcus Biosciences, Inc. Amended Compensation Program for Non-Employee Directors Effective as of June 10, 2025

from 10-K 8 pages January 16, 2025 Dimitry Nuyten, MD, PH.D. [Address]

from 10-K 4 pages January 13, 2025 Richard Markus, M.D., PH.D. [Address]

from 10-Q 2 pages Amendment No. 4 to Option, License and Collaboration Agreement

from 8-K 2 pages Arcus Biosciences, Inc. Amended Compensation Program for Non-Employee Directors Effective as of June 6, 2024

from 10-K 16 pages Confidential Execution Version

from 10-K 11 pages Arcus Biosciences, Inc. Severance Benefits Plan Effective as of February 20, 2024

from 10-Q 3 pages [***] = Information Has Been Omitted Because It Is Both Not Material and Is the Type of Information That Arcus Biosciences, Inc. Treats as Private or Confidential Memorandum

from 10-Q 22 pages [***] Certain Information Has Been Omitted Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed Amendment No. 2 to Option, License and Collaboration Agreement

from 8-K 3 pages Arcus Biosciences, Inc. Amended Compensation Program for Non-Employee Directors Effective as of June 15, 2023

from 10-K 6 pages [***] = Information Has Been Omitted Because It Is Both Not Material and Is the Type of Information That Arcus Biosciences, Inc. Treats as Private or Confidential Amendment No. 4 to License Agreement

from 10-Q 4 pages Material contract

from 8-K 2 pages Amendment No. 1 to Investor Rights Agreement

from 10-Q 6 pages [***] = Information Has Been Omitted Because It Is Both Not Material and Is the Type of Information That Arcus Biosciences, Inc. Treats as Private or Confidential

from 8-K 3 pages 1. Retainer for Each Non-Employee Member of the Board: $45,000 2. Additional Retainer for Lead Independent Director: $5,000 3. Additional Retainer for Chair of Audit Committee: $20,000 4. Additional Retainer for Chair of Compensation Committee: $15,000 5. Additional Retainer for Chair of Nominating and Corporate Governance Committee: $10,000 6. Additional Retainer for Non-Chair Members of Audit Committee: $10,000 7. Additional Retainer for Non-Chair Members of Compensation Committee: $7,500 8. Additional Retainer for Non-Chair Member of Nominating and Corporate Governance Committee: $5,000 B. Equity Compensation

from 10-K 15 pages [***] = Information Has Been Omitted Because It Is Both Not Material and Is the Type of Information That Arcus Biosciences, Inc. Treats as Private or Confidential Amendment No. 1 to Option, License and Collaboration Agreement

from 10-K 21 pages Arcus Biosciences, Inc. 2020 Inducement Plan Adopted by the Board of Directors: January 22, 2020 Amended: November 24, 2020 Amended: February 18, 2021 Amended: December 27, 2021